Around ten years ago, the Food and Drug Administration (FDA) acknowledged the unmet need — and urgency — of including patient perspective in drug and device development in a systematic way.

Around ten years ago, the Food and Drug Administration (FDA) acknowledged the unmet need — and urgency — of including patient perspective in drug and device development in a systematic way.
While patient-reported outcomes are becoming increasingly standard in clinical trials, their impact still needs to be fully understood. Clinical trials, like peer-reviewed journals, face scrutiny and require rigorous analysis before results can be considered confirmatory.
Patient-reported outcomes (PROs) are clinical trial measures that capture the patient’s own perspective on how they feel. While they are commonly used in clinical trials, they are also used in the clinic as another measure to gauge a patient’s health over time.
Interest — social, financial, and academic — in artificial intelligence has exploded in the last decade: Since 2016, an ETF focused on artificial intelligence and robotics has jumped 148%.
One devastating consequence of dementias is how they degrade a person’s sense of self. This aspect of dementia has a crater-sized impact on those with dementia, but the progressive cognitive decline also enacts compounded suffering on their loved ones.
The history of neuroscience is marked by a series of milestones, all of which were developed by previous milestones. As is the way of science, not every milestone in the history of neuroscience has proven to be true.
Neurological conditions can be challenging to diagnose when many symptoms affect brain function and behaviors, which can be obscured or misinterpreted as other diagnoses. In many cases, diagnoses overlap, with multiple conditions responsible for a patient’s symptoms.
An estimated half of autism diagnoses concur with epilepsy, but researchers don’t fully understand why.